Should You Invest in Apellis Pharmaceuticals Inc (APLS) Now?

The 36-month beta value for APLS is at 0.90. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for APLS is 98.84M, and currently, shorts hold a 10.72% of that float. The average trading volume for APLS on April 04, 2024 was 1.56M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

APLS) stock’s latest price update

Apellis Pharmaceuticals Inc (NASDAQ: APLS)’s stock price has plunge by 2.24relation to previous closing price of 55.70. Nevertheless, the company has seen a -3.47% plunge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-02-28 that Apellis’ (APLS) fourth-quarter 2023 bottom line misses estimates, while the top line meets the same. The newly approved product, Syfovre, drives year-over-year sales.

APLS’s Market Performance

Apellis Pharmaceuticals Inc (APLS) has seen a -3.47% fall in stock performance for the week, with a -11.88% decline in the past month and a -7.05% plunge in the past quarter. The volatility ratio for the week is 4.53%, and the volatility levels for the past 30 days are at 4.34% for APLS. The simple moving average for the past 20 days is -2.25% for APLS’s stock, with a 4.14% simple moving average for the past 200 days.

Analysts’ Opinion of APLS

Many brokerage firms have already submitted their reports for APLS stocks, with Jefferies repeating the rating for APLS by listing it as a “Buy.” The predicted price for APLS in the upcoming period, according to Jefferies is $80 based on the research report published on February 05, 2024 of the current year 2024.

Goldman gave a rating of “Buy” to APLS, setting the target price at $74 in the report published on November 09th of the previous year.

APLS Trading at -9.77% from the 50-Day Moving Average

After a stumble in the market that brought APLS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.89% of loss for the given period.

Volatility was left at 4.34%, however, over the last 30 days, the volatility rate increased by 4.53%, as shares sank -8.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -12.99% lower at present.

During the last 5 trading sessions, APLS fell by -3.47%, which changed the moving average for the period of 200-days by -36.44% in comparison to the 20-day moving average, which settled at $57.98. In addition, Apellis Pharmaceuticals Inc saw -4.86% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at APLS starting from Sullivan Timothy Eugene, who sale 4,000 shares at the price of $58.66 back on Apr 01 ’24. After this action, Sullivan Timothy Eugene now owns 93,338 shares of Apellis Pharmaceuticals Inc, valued at $234,640 using the latest closing price.

Dunlop A. Sinclair, the Director of Apellis Pharmaceuticals Inc, sale 18,681 shares at $57.18 during a trade that took place back on Mar 19 ’24, which means that Dunlop A. Sinclair is holding 173,998 shares at $1,068,161 based on the most recent closing price.

Stock Fundamentals for APLS

Current profitability levels for the company are sitting at:

  • -1.37 for the present operating margin
  • 0.85 for the gross margin

The net margin for Apellis Pharmaceuticals Inc stands at -1.37. The total capital return value is set at -0.98. Equity return is now at value -290.14, with -68.26 for asset returns.

Based on Apellis Pharmaceuticals Inc (APLS), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -5.98. The debt to equity ratio resting at 0.51. The interest coverage ratio of the stock is -35.31.

Currently, EBITDA for the company is -515.42 million with net debt to EBITDA at 0.47. When we switch over and look at the enterprise to sales, we see a ratio of 17.19. The receivables turnover for the company is 1.87for trailing twelve months and the total asset turnover is 0.49. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.10.


In conclusion, Apellis Pharmaceuticals Inc (APLS) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts